Summary
Long-term follow-up of parkinsonian patients has shown that although levodopa treatment significantly improves the parkinsonian symptoms and the quality of life of parkinsonian patients for several years, various distressing difficulties arise during chronic levodopa treatment, such as the loss of benefit, dyskinesias, on-off phenomena, postural instability and dementia. Clinical, neuropsychological, mortality and post-mortem brain studies indicate that levodopa as a replacement therapy does not modify the progression of the underlying pathology and the natural course of the disease. It seems that levodopa has only a limited period of optimal usefulness in the treatment of Parkinson's disease. However, at present there is no better or more potent therapeutic agent available than levodopa and it is still the primary treatment of Parkinson's disease. It would be reasonable not to begin levodopa treatment in patients with mild symptoms but to withold levodopa until the severity of symptoms really makes its use necessary. Thus it is possible to get the maximal long functional benefit.
Post-mortem brain studies have shown that in Parkinson's disease there is not only a progressive loss of dopaminergic substantia nigra neurons but there are also significant changes in the striatal dopamine receptors. In some patients a denervation supersensitivity seems to develop and in some others a loss of dopamine receptors in the striatum. However, in advanced parkinsonian patients with a deteriorating response to levodopa, there seem to be still enough dopamine receptors in the striatum for drugs stimulating the dopamine receptors directly to improve the parkinsonian disability. Indeed, recent evidence indicates that dopaminergic agonists, such as bromocriptine, seem to be a significant and valuable adjuvant therapy to levodopa in parkinsonian patients with a deteriorating response and/or the on-off phenomena. Although bromocriptine is not completely satisfactory, it is a significant opening to a new mode of treatment. In the future it will be very important to develop more potent and selective dopaminergic agonists affecting only those striatal receptors which are mainly responsible for the parkinsonian symptoms. Then a better therapeutic response is likely to occur and many central side effects can be avoided.
Current difficulties in the management of Parkinson's disease greatly depend on the fact that we are dealing with a symptomatic therapy. It is hoped that future research will soon lead to a discovery of the primary cause and consequently to a causal therapy of Parkinson's disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alvord, E. C., Forno, L. S., Kusske, J. A.: A comparison of degeneration in cerebral cortex and brainstem. Adv. Neurol.5, 175–193 (1974).
Barbeau, A.: The clinical physiology of side-effects in long-term L-DOPA therapy. In: Advances in Neurology (McDowell, F. H., Barbeau, A., eds.), pp. 347–365. New York: Raven Press. 1974.
Barbeau, A.: Pathophysiology of the oscillations in performance after longterm therapy with L-Dopa. In: Advances in Parkinsonism (Birkmayer, W., Hornykiewicz, O., eds.), pp. 424–434. Basle: Editiones Roche. 1976.
Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastman, R., Greenacre, J. K., Petrie, A.: Bromocriptine in parkinsonism. Br. Med. J.4, 442–444 (1974).
Calne, D. B., Plotkin, C., Williams, A. C., Nutt, J. G., Neophytides, A., Teychenne, P. F.: Long-term treatment of parkinsonism with bromocriptine. LancetI, 735–738 (1978).
Claveria, L. E., Calne, D. B., Allen, J. G.: “On-off” phenomena related to high plasma levodopa. Br. Med. J.1, 641–643 (1973).
Cotzias, G. C., Papavasiliou, P. S., Tolosa, E. S., Mendez, J. S., Bell-Midura, M.: Treatment of Parkinson's disease with apomorphines. N. Engl. J. Med.294, 567–572 (1976).
Diamond, S. G., Markham, Ch. H.: Present mortality in Parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths. J. Neural Transm.38, 259–269 (1976).
Diamond, S. G., Markham, Ch. H.: Mortality of parkinsonian patients treated with Sinemet. In: Advances in Neurology, Vol. 24 (Poirier, L. J., Sourkes, T. L., Bédard, P. J., eds.), pp. 489–497. New York: Raven Press. 1979.
Direnfeld, L., Spero, L., Marotta, J., Seeman, P.: The L-Dopa on-off effect in Parkinson disease: Treatment by transient drug withdrawal and dopamine receptor resensitization. Ann. Neurol.4, 573–575 (1978).
Dougan, D., Wade, D., Mearrick, P.: Effects of L-dopa metabolites at a dopamine receptor suggest a basis for “on-off” effect in Parkinson's disease. Nature254, 70–72 (1975).
Fahn, S.: “On-off” phenomenon with levodopa therapy in parkinsonism-Clinical and pharmacologic correlations and the effect of intramuscular pyridoxone. Neurology24, 431–441 (1974).
Fahn, S.: Medical treatment of movement disorders. In: Neurological Reviews, pp. 72–106. Minneapolis: American Academy of Neurology. 1976.
Fahn, S., Cote, L. J., Snider, S. R., Barrett, R. E., Isgreen, W. P.: The role of bromocriptine in the treatment of parkinsonism. Neurology29, 1077–1083 (1979).
Farley, I. J., Hornykiewicz, O.: Noradrenaline in subcortical brain regions of patients with Parkinson's disease and control subjects. In: Advances in Parkinsonism (Birkmayer, W., Hornykiewicz, O., eds.), pp. 178–185. Basle: Editiones Roche. 1976.
Farley, I. J., Price, K. S., Hornykiewicz, O.: Dopamine in the limbic regions of the human brain: normal and abnormal. In: Advances in Biochemical Psychopharmacology, Vol. 16 (Costa, E., Gessa, G. L., eds.), pp. 57–64. New York: Raven Press. 1977.
Grøn, U.: Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease. Acta neurol. Scand.56, 269–273 (1977).
Hakim, A. M., Matheson, G.: Dementia in Parkinson's disease: a neuropathologic study. Neurology29, 1209–1214 (1979).
Hoehn, M. M., Yahr, M. D.: Parkinsonism: onset, progression and mortality. Neurology17, 427–442 (1967).
Jansen, E. N. H.: Bromocryptine in levodopa response-losing parkinsonism. Eur. Neurol.17, 92–99 (1978).
Joseph, C., Chassan, J. B., Koch, M.-L.: Levodopa in Parkinson disease: A long-term appraisal of mortality. Ann. Neurol.3, 116–118 (1978).
Kartzinel, R., Calne, D. B.: Studies with bromocriptine: I. “On-off” phenomena. Neurology26, 508–510 (1976).
Lee, T., Seeman, P., Rajput, A., Farley, I. J., Hornykiewicz, O.: Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature273, 59–61 (1978).
Lesser, R. P., Fahn, S., Snider, S. R., Cote, L. J., Isgreen, W. P., Barrett, R. E.: Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology29, 1253–1260 (1979).
Lieberman, A., Zolfaghari, M., Boal, D., Hassouri, H., Vogel, B., Battista, A., Fuxe, K., Goldstein, M.: The antiparkinsonian efficacy of bromocriptine. Neurology26, 405–409 (1976).
Lieberman, A., Estey, E., Kupersmith, M., Gopinathan, G., Goldstein, M.: Treatment of Parkinson's disease with lergotrile mesylate. J. Amer. Med. Ass.238, 2380–2382 (1977).
Lieberman, A., Dziatolowski, M., Kupersmith, M., Serby, M., Goodgold, A., Korein, J., Goldstein, M.: Dementia in Parkinson's disease. Ann. Neurol.6, 355–359 (1979).
Marsden, C. D.: “On-off phenomena” in Parkinson's disease. In: Parkinson's Disease-Current Progress, Problems and Management (Rinne, U. K., Klingler, M., Stamm, G., eds.), pp. 241–254. Amsterdam: Elsevier. 1980.
Marsden, C. D., Parkes, J. D.: “On-off” effects in patients with Parkinson's disease on chronic levodopa therapy. LancetI, 292–295 (1976).
Marttila, R. J., Rinne, U. K., Siirtola, T., Sonninen, V.: Mortality of patients with Parkinson's disease treated with levodopa. J. Neurol.216, 147–153 (1977).
Parkes, J. D., Marsden, C. D., Donaldson, I.: Bromocriptine treatment in Parkinson's disease. J. Neurol. Neurosurg. Psychiat.39, 184–193 (1976).
Portin, R., Rinne, U. K.: Neuropsychological responses of parkinsonian patients to long-term levodopa treatment. In: Parkinson's Disease-Current Progress, Problems and Management (Rinne, U. K., Kling1er, M., Stamm, G., eds.), pp. 271–304. Amsterdam: Elsevier. 1980.
Reisine, T. D., Fields, J. Z., Yamamura, H. I.: Neurotransmitter receptor alterations in Parkinson's disease. Life Sci.21, 335–344 (1977).
Riederer, P., Birkmayer, W., Seemann, D., Wuketich, St.: Brain noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome. J. Neural Transm.41, 241–251 (1977).
Rinne, U. K.: Recent advances in research on Parkinsonism. Acta neurol. Scand.57, 77–113 (1978).
Rinne, U. K.: Recent advances in the treatment of Parkinson's disease. Acta neurol. Scand.62, 103–121 (1980).
Rinne, U. K., Sonninen, V.: Brain catecholamines and their metabolites in parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor. Arch. Neurol.28, 107–110 (1973).
Rinne, U. K., Marttila, R. J.: Brain dopamine receptor stimulation and the relief of Parkinsonism. Relationship between bromocriptine and levodopa. Ann. Neurol.4, 263–267 (1978).
Rinne, U. K., Sonninen, V., Riekkinen, P., Laaksonen, H.: Post-mortem findings in parkinsonian patients treated with L-Dopa: Biochemical considerations. In: Current Concepts in the Treatment of Parkinsonism (Yahr, M. D., ed.), pp. 211–233. New York: Raven Press. 1974.
Rinne, U. K., Sonninen, V., Siirtola, T.: Long-term treatment of Parkinsonism with L-Dopa and decarboxylase inhibitor: a clinical and biochemical approach. In: Advances in Parkinsonism (Birkmayer, W., Hornykiewicz, O., eds.), pp. 555–573. Basle: Editiones Roche. 1976.
Rinne, U. K., Marttila, R. J., Sonninen, V.: Brain dopamine turnover and the relief of Parkinsonism. Arch. Neurol.34, 626–629 (1977).
Rinne, U. K., Sonninen, V., Laaksonen, H.: Responses of brain neurochemistry to levodopa treatment in Parkinson's disease. In: Advances in Neurology, Vol. 24 (Poirier, L. J., Sourkes, T. L., Bédard, J. P., eds.), pp. 259–274. New York: Raven Press. 1979.
Rinne, U. K., Sonninen, V., Siirtola, T., Marttila, R.: Long-term responses of Parkinson's disease to levodopa therapy. J. Neural Transm.16, 149–156 (1980 a).
Rinne, U. K., Koskinen, V., Lönnberg, P.: Neurotransmitter receptors in the parkinsonian brain. In: Parkinson's Disease-Current Progress, Problems and Management (Rinne, U. K., Klingler, M., Stamm, G., eds.), pp. 93–107. Amsterdam: Elsevier. 1980 b.
Schneider, E., Fischer, P. A., Jacobi, P., Becker, H., Hacker, H.: The significance of cerebral atrophy for the symptomatology of Parkinson's disease. J. Neurol. Sci.42, 187–197 (1979).
Selby, G.: Cerebral atrophy in Parkinsonism. J. Neurol. Sci.6, 517–559 (1968).
Shoulson, I., Glaubiger, G. A., Chase, T. N.: On-off response: Clinical and biochemical correlations during oral and intravenous levodopa administration to parkinsonian patients. Neurology25, 1144–1148 (1975).
Stern, G. M., Lees, A. J., Sandler, M.: Recent observations on the clinical pharmacology of (-)Deprenyl. J. Neural Transm.43, 245–251 (1978).
Sweet, R. D., McDowell, F. H.: Plasma dopa levels on the “on-off” effect in Parkinson's disease. Neurology10, 953 (1974).
Sweet, R. D., McDowell, F. H.: Five years' treatment of Parkinson's disease with levodopa. Ann. Int. Med.83, 456–463 (1975).
Tolosa, E. S., Martin, W. E., Cohen, H. P.: Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology25, 177–183 (1975).
Wolf, S. M., Davis, R. C.: Permanent dementia in idiopathic parkifisonism treated with levodopa. Arch. Neurol.29, 276–278 (1973).
Yahr, M. D.: Evaluation of long-term therapy in Parkinson's disease: mortality and therapeutic efficacy. In: Advances in Parkinsonism (Birkmayer, W., Hornykiewicz, O., eds.), pp. 435–443. Basle: Editiones Roche. 1976.
Yahr, M. D.: Overview of present day treatment of Parkinson's disease. J. Neural Transm.43, 227–238 (1978).
Zumstein, H., Siegfried, J.: Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. Eur. Neurol.14, 321–327 (1976).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rinne, U.K. Treatment of Parkinson's disease: Problems with a progressing disease. J. Neural Transmission 51, 161–174 (1981). https://doi.org/10.1007/BF01664013
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01664013